Hannah Snyder1, Mariah M Kalmin2, Aimee Moulin3, Arianna Campbell4, David Goodman-Meza5, Howard Padwa6, Serena Clayton7, Melissa Speener7, Steve Shoptaw2, Andrew A Herring8. 1. Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA; CA Bridge Program, Public Health Institute, Oakland, CA. 2. Department of Family Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA. 3. CA Bridge Program, Public Health Institute, Oakland, CA; Department of Emergency Medicine and Psychiatry, UC Davis Medical Center, Sacramento, CA. 4. CA Bridge Program, Public Health Institute, Oakland, CA; Department of Emergency Medicine, US Acute Care Solutions at Marshall Medical Center, Placerville, CA. 5. Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA. 6. Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA. 7. CA Bridge Program, Public Health Institute, Oakland, CA. 8. CA Bridge Program, Public Health Institute, Oakland, CA; Department of Emergency Medicine and Internal Medicine, Highland Hospital-Alameda Health System, Oakland, CA; University of California San Francisco, San Francisco, CA. Electronic address: Aherring@alamedahealthsystem.org.
Abstract
STUDY OBJECTIVE: We retrospectively evaluated the implementation of low-threshold emergency department (ED) buprenorphine treatment at 52 hospitals participating in the CA Bridge Program using the RE-AIM (reach, effectiveness, adoption, implementation, maintenance) framework. METHODS: The CA Bridge model included low-threshold buprenorphine, connection to outpatient care, and harm reduction. Implementation began in March 2019. Participating hospitals reported aggregated clinical data monthly after program initiation. Outcomes included identification of opioid use disorder, buprenorphine administration, and linkage to outpatient addiction treatment. Multivariable models assessed associations between hospital location (rural versus urban) and teaching status (clinical teaching hospital versus community hospital) and outcomes in adopting the CA Bridge Program. RESULTS: Reach: A diverse and geographically distributed group of 52 California hospitals were enrolled in 2 phases (March and August 2019); 12 (23%) were rural and 13 (25%) were teaching hospitals. Effectiveness: Over a 14-month implementation period, 12,009 opioid use disorder patient encounters were identified, including 7,179 (59.7%) where buprenorphine was administered and 4,818 (40.1%) where follow-up visits were attended. Adoption: In multivariable analysis, adoption did not differ significantly between rural and urban or teaching and nonteaching hospitals. IMPLEMENTATION: By program completion, all 52 (100%) hospitals treated opioid use disorder with buprenorphine; 45 (86.5%) administered buprenorphine after naloxone reversal; 41 (84.6%) offered buprenorphine for inpatients; 48 (92.3%) initiated buprenorphine in pregnant women; and 29 (55.8%) offered take-home naloxone. Maintenance: At 8-month follow-up, all 52 sites reported continued buprenorphine treatment. CONCLUSION: Low-threshold ED buprenorphine treatment implemented with a harm reduction approach and active navigation to outpatient addiction treatment was successful in achieving buprenorphine treatment for opioid use disorder in diverse California communities.
STUDY OBJECTIVE: We retrospectively evaluated the implementation of low-threshold emergency department (ED) buprenorphine treatment at 52 hospitals participating in the CA Bridge Program using the RE-AIM (reach, effectiveness, adoption, implementation, maintenance) framework. METHODS: The CA Bridge model included low-threshold buprenorphine, connection to outpatient care, and harm reduction. Implementation began in March 2019. Participating hospitals reported aggregated clinical data monthly after program initiation. Outcomes included identification of opioid use disorder, buprenorphine administration, and linkage to outpatient addiction treatment. Multivariable models assessed associations between hospital location (rural versus urban) and teaching status (clinical teaching hospital versus community hospital) and outcomes in adopting the CA Bridge Program. RESULTS: Reach: A diverse and geographically distributed group of 52 California hospitals were enrolled in 2 phases (March and August 2019); 12 (23%) were rural and 13 (25%) were teaching hospitals. Effectiveness: Over a 14-month implementation period, 12,009 opioid use disorder patient encounters were identified, including 7,179 (59.7%) where buprenorphine was administered and 4,818 (40.1%) where follow-up visits were attended. Adoption: In multivariable analysis, adoption did not differ significantly between rural and urban or teaching and nonteaching hospitals. IMPLEMENTATION: By program completion, all 52 (100%) hospitals treated opioid use disorder with buprenorphine; 45 (86.5%) administered buprenorphine after naloxone reversal; 41 (84.6%) offered buprenorphine for inpatients; 48 (92.3%) initiated buprenorphine in pregnant women; and 29 (55.8%) offered take-home naloxone. Maintenance: At 8-month follow-up, all 52 sites reported continued buprenorphine treatment. CONCLUSION: Low-threshold ED buprenorphine treatment implemented with a harm reduction approach and active navigation to outpatient addiction treatment was successful in achieving buprenorphine treatment for opioid use disorder in diverse California communities.
Authors: Caroline A King; Ryan Cook; Haven Wheelock; P Todd Korthuis; Judith M Leahy; Amelia Goff; Cynthia D Morris; Honora Englander Journal: Int J Drug Policy Date: 2021-11-24
Authors: Jessica Heil; Valerie S Ganetsky; Matthew S Salzman; Krystal Hunter; Kaitlan E Baston; Gerard Carroll; Eric Ketcham; Rachel Haroz Journal: West J Emerg Med Date: 2022-04-04
Authors: Lauren K Whiteside; Ly Huynh; Sophie Morse; Jane Hall; William Meurer; Caleb J Banta-Green; Hannah Scheuer; Rebecca Cunningham; Mark McGovern; Douglas F Zatzick Journal: J Subst Abuse Treat Date: 2021-11-24
Authors: Edward R Melnick; Bidisha Nath; James D Dziura; Martin F Casey; Molly M Jeffery; Hyung Paek; William E Soares; Jason A Hoppe; Haseena Rajeevan; Fangyong Li; Rachel M Skains; Lauren A Walter; Mehul D Patel; Srihari V Chari; Timothy F Platts-Mills; Erik P Hess; Gail D'Onofrio Journal: BMJ Date: 2022-06-27